Irritability Associated With Autism Spectrum Disorder

4
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
2
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
PIMAVANSERINApproved
pimavanserin
Unknown Company
oral

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
2 programs
2
PimavanserinPhase 2/31 trial
PimavanserinPhase 2/31 trial
Active Trials
NCT05555615Terminated209Est. Feb 2025
NCT05523895Completed237Est. Sep 2024
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
JZP541Phase 21 trial
Active Trials
NCT05733390Withdrawn0Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Acadia PharmaceuticalsPimavanserin
Jazz PharmaceuticalsJZP541

Clinical Trials (3)

Total enrollment: 446 patients across 3 trials

NCT05555615Acadia PharmaceuticalsPimavanserin

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Start: Nov 2022Est. completion: Feb 2025209 patients
Phase 2/3Terminated
NCT05523895Acadia PharmaceuticalsPimavanserin

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Start: Aug 2022Est. completion: Sep 2024237 patients
Phase 2/3Completed
NCT05733390Jazz PharmaceuticalsJZP541

A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

Start: Jun 2023Est. completion: Nov 20230
Phase 2Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space